Yahoo India Web Search

Search results

  1. For medically inoperable patients with a single GGN manifesting early-stage lung cancer and patients with multiple primary early-stage lung cancers which cannot be resected at the same time, ENB-guided MWA might be a safe and feasible alternative local treatment, whether combined with surgical resec …

  2. Jun 1, 2021 · Our results here showed that anti-IFN-γ therapy alleviated the acute lung injury in this mouse model. Neutralization of IFN-γ led to a significant reduction in the lung microvascular leak and the cellular infiltrate in the lung tissue, and also improved the outcome in mice mortality.

    • Bo Liu, LinLin Bao, Li Wang, Fengdi Li, Mingjie Wen, Hui Li, Wei Deng, Xulong Zhang, Bin Cao
    • 2021
  3. Bao-Lung Wang is Former Board Member at Fupo Electronics Corp. See Bao-Lung Wang's compensation, career history, education, & memberships.

    • Former Board Member
    • Fupo Electronics Corp
  4. May 30, 2023 · A recent article by Wang and colleagues reported an integrated model utilizing five machine learning algorithms on five different cfDNA fragmentomics features for detecting early-stage lung cancer. The integrated model yielded high AUCs in both validation cohorts (0.984 and 0.987; ref. 18 ).

    • 10.1158/2767-9764.CRC-22-0363
    • 2023/05
    • Cancer Res Commun. 2023 May; 3(5): 933-942.
  5. Jan 3, 2022 · In the present study, a multimodality MRI-based radiomics approach obtained an AUC of 0.930 in primary cohort, and an AUC of 0.852 in validation cohort, which showed high prediction performance and clinical gain.

  6. In this study, we focused to determine the expression of circulating lncRNAs in patients suffering from non-small-cell lung cancer (NSCLC), aiming … Recent studies have indicated that long non-coding RNAs (lncRNAs) could act as non-invasive tumor markers in both diagnosis and predicting the prognosis.

  7. Oct 9, 2015 · Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.